NRIXNurix Therapeutics, Inc.

1. Jul 9, 2026Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
2. Jun 11, 2026On June 11, 2026, the Company announced updated data from the Phase 1 clinical trial of bexobrutideg (NX-5948)Regulation FD disclosure · Form 8-K
3. Jun 8, 2026On June 6, 2026, Nurix Therapeutics, Inc. (“Nurix”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “Roche”), pursuant to which Nurix will grant Roche an exclusive worldwide license …Material agreement entered · Form 8-K
4. Apr 8, 2026Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update.Earnings release · press release
5. Mar 6, 2026As previously disclosed, on August 4, 2021, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”), which Equity Distribution Agreement was subsequently amended by Amendment No. 1 …Other event · Form 8-K
6. Jan 28, 2026Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update.Earnings release · press release
7. Jan 12, 2026Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases.Regulation FD disclosure · press release
8. Dec 9, 2025On December 6, 2025, the Company announced new clinical data from the Phase 1a/1b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory CLL and SLL, and on December 8, 2025, the Company announced new clinical data from patients with relapsed or refractory Waldenström macroglobulinemia (WM) …Regulation FD disclosure · Form 8-K
9. Nov 10, 2025On November 6, 2025, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Roger Dansey, M.D., to serve as a director of the Company and as a member of the Clinical and …Director or officer change · Form 8-K
10. Oct 22, 2025On October 22, 2025, the Company announced the initiation of the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of its Bruton tyrosine kinase (“BTK”) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (“r/r CLL/SLL”)Regulation FD disclosure · Form 8-K
11. Oct 22, 2025On October 22, 2025, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Stifel, Nicolaus & Company, Incorporated as the representatives of the several underwriters named in Schedule 1 thereto (the …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.